PD-1 inhibitor

Phase 2

BioAtla, Inc. (BCAB)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Non-Small-Cell Lung Cancer

SNYoxaliplatine / gemcitabine / Vinorelbine

Drug Information

Target Indication

Non-Small-Cell Lung Cancer

Clinical Trial

NCT04681131

Last updated: 2/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BCAB

BioAtla, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

CAB-AXL-ADCPhase 2

Undifferentiated Pleomorphic Sarcoma

BA3071Phase 2

NSCLC

CAB-ROR2-ADCPhase 2

Non Small Cell Lung Cancer

Ozuriftamab VedotinPhase 2

Head and Neck Cancer

BA3011Phase 2

Ovarian Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts